Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

D. R. Session, K. R. Kalli, I. S. Tummon, M. A. Damario, D. A. Dumesic

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an insulin-sensitizing agent. A 37-year-old patient presented after failed treatment of endometrial hyperplasia with progestogen therapy. One month after initiating metformin therapy the patient's endometrial biopsy demonstrated proliferative endometrium. This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent. This relatively new class of drugs may provide an adjunct to the therapy of endometrial hyperplasia.

Original languageEnglish (US)
Pages (from-to)405-407
Number of pages3
JournalGynecological Endocrinology
Volume17
Issue number5
DOIs
StatePublished - Oct 1 2003

Keywords

  • Endometrium
  • Hyperplasia
  • Insulin
  • Metformin
  • Progestogen

Fingerprint Dive into the research topics of 'Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent'. Together they form a unique fingerprint.

Cite this